Keratinocyte gene therapy for systemic diseases. Circulating interleukin 10 released from gene-transferred keratinocytes inhibits contact hypersensitivity at distant areas of the skin.
about
Transfection of IL-10 expression vectors into endothelial cultures attenuates alpha4beta7-dependent lymphocyte adhesion mediated by MAdCAM-1Polymorphism of the glutathione transferase subunit 3 in Sprague-Dawley rats involves a reactive cysteine residueGene therapy and dermatology: more than just skin deep.Cutaneous gene transfer and therapy: the present and the future.Direct injection of naked DNA and cytokine transgene expression: implications for keratinocyte gene therapy.Different role of IL-4 in the onset of hapten-induced contact hypersensitivity in BALB/c and C57BL/6 mice.Current approaches and perspectives in human keratinocyte-based gene therapies.Cutaneous gene therapy.Effector and regulatory mechanisms in allergic contact dermatitis.Contact dermatitis: a comparative and translational review of the literature.Keratinocyte gene therapy: inducible promoters and in vivo control of transgene expression.In vivo gene introduction into keratinocytes using jet injection.Transfection of normal human epidermal keratinocytes with lipid/dna complexes in vitro.Topical glucocorticoids application induced an augmentation in the expression of IL-1alpha while inhibiting the expression of IL-10 in the epidermis in murine contact hypersensitivity.Suppression of cutaneous inflammation by intradermal gene delivery.Keratinocyte gene therapy: cytokine gene expression in local keratinocytes and in circulation by introducing cytokine genes into skin.
P2860
Q24805188-40BE7E3D-C79D-42E9-B730-EFF3CADFB7C3Q30905930-D840EA7A-27FB-414D-A6D8-9C60B4D59B55Q33669657-91D2496E-C1D2-47C8-8302-EE9841806D92Q34195600-4C96063A-7A23-4E44-949D-84D454BFFE45Q34952652-702EC17D-590A-4525-8555-E8BAC0381E54Q35041837-81D6A212-1B34-450E-9FEC-6C5C916DC918Q35904434-26E6D4C6-F273-433E-8309-16765C05DBCEQ36799389-07086053-7240-4450-89F3-2727C90071FBQ37617470-B994F191-C095-4B62-87DC-99FF60B3E9B3Q38549107-2FD8B82E-8D0A-41DC-BE1B-B0E3EA030A7AQ40772302-93DC5241-DF8E-4678-A1CC-2241AC2F6B09Q40794221-8692FD4D-0458-4C45-B284-FD5AFB643B57Q42455498-6F56D159-F069-46BF-8327-B9161C969650Q43548744-D79F0EE3-BB91-4DA2-BB05-98548CEA6696Q44444073-9F0FF300-C49F-4820-BA8E-73A4C4AA33A9Q45855299-BEA62BC8-4F6A-41B4-BC7D-757A70705411
P2860
Keratinocyte gene therapy for systemic diseases. Circulating interleukin 10 released from gene-transferred keratinocytes inhibits contact hypersensitivity at distant areas of the skin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 1998
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Keratinocyte gene therapy for ...... at distant areas of the skin.
@en
Keratinocyte gene therapy for ...... at distant areas of the skin.
@nl
type
label
Keratinocyte gene therapy for ...... at distant areas of the skin.
@en
Keratinocyte gene therapy for ...... at distant areas of the skin.
@nl
prefLabel
Keratinocyte gene therapy for ...... at distant areas of the skin.
@en
Keratinocyte gene therapy for ...... at distant areas of the skin.
@nl
P2093
P2860
P356
P1476
Keratinocyte gene therapy for ...... at distant areas of the skin.
@en
P2093
P2860
P304
P356
10.1172/JCI1031
P407
P577
1998-03-01T00:00:00Z